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ABSTRACT
Detection o f Glial Interlcukin-6 Release: Development
o f a Novel Interleuldn-6 ELISA
by
Kay-Lynn Bowman
Dr. Bryan L. Spangelo, Examination Committee Chair
Associate Professor and Chair o f the Department o f Chemistry
University o f Nevada, Las Vegas
The development o f an interleukin-6 (IL-6) enzyme-linked immunosorbent (ELISA)
assay resulted in a detection range o f 1 ng/ml to 10 ng/mL IL-6. The limit o f detection
(LOD) for IL-6 was 0.25 ng/mL. Troubleshooting techniques were attempted including
matrix effects, non-specific binding, and coating buffer pH differences. In comparison to
the ELISA, the LOD for IL-6 using the 7TDI bioassay was 2-5 pg/mL. Therefore the
7TDI bioassay was implemented for the experiments described in this study. IL-6 is a
cytokine known to stimulate B-cell differentiation and to activate T-cells. IL-6 is
elevated in inflammatory and neurodegenerative diseases. Interleukin-Ip (IL-IP)
stimulates IL-6 release from glial cells. Catecholamines and IL -ip synergistically release
IL-6 from glial cells. In the rat C6 glioma cell line, the role o f indoleamines was
examined alone and in combination with IL -ip resulting in no synergistic effects on IL-6
release. Isoproterenol synergistically acted with IL -ip on stimulating IL-6 release. IL-I
receptor antagonist decreased the IL -ip stimulation o f IL-6. These results demonstrate
that the catecholamines and IL -ip play a role in the regulation o f IL-6 expression.
iii
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CHAPTER 1
INTRODUCTION
Background and Project Description
This study includes the development of an ELISA and the continuing investigations
o f IL-6 release from C6 glioma cells. The attempt at developing a novel ELISA for the
detection o f IL-6 requires the understanding o f the types o f immunoassays available and
how they can be applied to a 96-well assay format. This will be discussed later in this
introductory section.
Cross-communication between the nervous/endocrine/immune systems is an
important area for understanding how each system contributes to homeostasis and
therefore will be discussed in general terms, lnterluekin-6, a cytokine released from glial
cells, plays a role in neurodegeneration. The regulation o f lL-6 release is important for
finding potential therapeutic interventions.
Specifically 1 intend the following;
1. To describe the development of the IL-6 ELISA including standard curve
data and trouble shooting techniques.
2. To determine what mechanisms control the release o f lL-6 from C6 cells
including the effects o f IL -lp, IL-lra, serotonin and melatonin.
3. To interpret data on the mechanisms o f IL-6 release to the potential effects
lL-6 has on neurodegeneration and inflammation.

1
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Several aspects o f human biochemistry are significant to the above stated goals. The
immune system, the neuroendocrine system, cytokines, and neurotransmitters are all
important topics that must be discussed to fully understand their relationship in
explaining what effects lL -6 has on neurodegeneration and in fla m m a tion

Immune System
The immune system is composed of two main components; the humoral immimg
response and the cell-mediated immune response. The humoral response allows for the
immune system to remember an infectious agent and prevent it fi’o m causing disease at a
later time. Cells o f the humoral response consist o f T and B lymphocytes (T and B cells).
B cells have the ability to release antibody that binds to its target antigen. The T cells
control B cell development and antibody production. The T cells release soluble factors
(cytokines) which activate phagocytes to destroy pathogenic material they engulf through
endocytosis (Roitt et al., 1993).
The cell-mediated immune response, acting as a first line o f defense against
infection, mainly consists o f leukocytes (e.g., monocytes, macrophages, and
polymorphonuclear neutrophils (PMNs)). Phagocytes are derived fi*om bone marrow
stem cells and function to engulf and destroy foreign particles that they encounter for
presentation as antigens to T cells. Phagocytes are present in the brain as microglial
cells, in the liver as Kupffer cells, in the blood as monocytes, and as macrophages in the
lung, spleen, and lymph tissues (Roitt et al., 1993).
The thymus, a primary lymphatic tissue, is responsible for the development o f
prothymocytes into mature T lymphocytes. Cells o f the thymus release thymic peptides
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and hormones such as thymosin a% (TaO, thymuiin and MB35 (Spangelo et al., 1997). A
thymic preparation o f the bovine thymus consisting o f low molecular weight peptides,
termed thymosin fraction 5 (TF5), has T lymphocyte-regulating properties (Spangelo,
1995). The thymic peptides and cytokines can influence T cell differentiation, and thus
the immune response. B cells develop in the bone marrow o f adult m am m als. Antigenic
stimulation results in the proliferation o f B cells and the differentiation o f these cells into
plasma cells or memory cells. Both T and B cells are important for aiding the immune
system to recognize pathogens. Their functions are coordinated to fight against infection.
The T cells accomplish this coordination by releasing cytokines (e.g., interferon,
interleukins, colony stimulating factors, and tumor necrosis factors) that signal B cells to
divide and differentiate into antibody secreting plasma cells. Antibody proteins have
specific binding regions; the Fab (fragment antigen binding) region for binding antigen
and the Fc (fragment crystallizable) that binds to phagocytes. It is the recognition o f the
antigen and the production o f antibodies against the antigen that allows for an immune
response.

Neuroendocrine System
The neuroendocrine system is composed o f specialized neuroendocrine cells found
in the hypothalamic region o f the brain. This region regulates the secretion o f hormones
from the pituitary gland (Cooper et al., 1996). The pituitary gland is composed o f both
glandular and neural tissue, thus allowing for a brain-pituitary axis. This axis is most
recognized in the hypothalamus-pituitary-adrenal (HPA) axis (Hadley, 1992). The
pituitary neural tissue forms the neurohypophysis and consists o f the median eminence.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

4
the infundibular stem, and the neural lobe (McCann et al., 1996). The pituitary receives
its blood supply from hypophysial arteries that penetrate the hypophysial stalk as well as
the hypothalamus. The anterior pituitary lobe is vascularized by hypophysial portal
vessels that arise from the capillary beds within the median eminence o f the
hypothalamus (i.e., the primary capillary plexus). The portal blood system originating in
the median eminence o f the hypothalamus sends vessels derived from this plexus down
the stalk to the anterior lobe to form the secondary capillary plexus. This vasculature
provides an important link for carrying hormonal information from the hypothalamus to
the pituitary (Figure 1) (Hadley, 1992). This link allows for hypothalam ic
neuroendocrine control o f adrenocorticotropic hormone (ACTH), growth hormone (GH),
thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and luteinizing
hormone (LH) secretion from the anterior pituitary (McCann et al., 1996). The central
nervous system (CNS) relays electrochemical signals through neuronal routes to release
neurotransmitters that affect synaptic transmission. These neurohormones include
monoamine neurotransmitters released from serotonergic, dopaminergic and
noradrenergic neuronal pathways. Axons from these neurons extend into the
hypothalamus to affect select nuclei. For example, noradrenergic pathways stimulate the
corticotropin releasing hormone (CRH) neurons in the paraventricular nucleus resulting
in enhanced CRH secretion and subsequently ACTH secretion from the anterior pituitary.

Interleukin Cytokines
Cytokines, mediators o f the immune response, have the ability to affect
neuroendocrine function and hormone secretion. The cytokine family o f peptides
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consists o f interleukins (1 to 18), tumor necrosis factor-a (TNF-a) and—P, colonystimulating factor (CSF), interferons, transforming growth factors-P, chemokines, and
growth factors (Casey, 1996). Cytokines can participate in a variety o f functions
including inflammation, to serve as growth or regulatory fectors, and to facilitate the
maintenance o f normal immune function. Interleukin-ip (IL-ip), TNF-a and sometimes
interleukin-6 (IL-6) are considered as inflammatory cytokines responsible for the acutephase response to infection (Arvin et al., 1996).
Interleukin-1 production by lymphocytes and monocytes affects in flam m ato ry and
cell-mediated immune responses by activation o f lymphocytes, macrophage stimulation,
increased endothelial adhesion, fever induction, and stimulation o f acute phase proteins
(Roitt et al., 1993). The lL-1 gene family consists o f IL -la, IL -ip and the IL-1 receptor
antagonist (IL-lra). IL -la and IL -ip are 22% homologous in terms o f their primary,
mature amino acid sequence. Both are synthesized as 31-kDa precursors (271 and 269
amino acids respectively) and are processed to 17.5-kDa molecular weight polypeptides
(159 and 153 amino acids respectively) (Spangelo, 1999). Precursor IL -la (ProIL-la)
is not normally secreted and remains predominantly intracellular. ProIL-lp is cleaved at
the cell surface by the IL-ip converting enzyme (ICE), and allows for the secretion o f the
biologically active, mature form o f IL -ip. IL-lra stqxpresses the biological activity o f ILl a and IL -ip by binding to an lL-1 receptor and not inducing an intracellular signaling
response. IL -lra is synthesized with a signal peptide and can be readily transported out
o f cells (Dinarello, 1997). The primary amino acid sequence homology for IL -lra and
£L-ip is 26%, which is greater than that between IL -la and IL -ip.
There are two types o f receptors for IL-1 binding. Type I and Type H. IL -lp has two
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binding sites on the IL-1 Type 1 receptor allowing for intracellular signaling to occur. EL1P can also bind lL-1 Type II receptors, but binding does not transduce an intracellular
signal. Therefore, the IL-1 Type H receptor is a decoy receptor for IL -ip binding. The
lL-1 Type 1 receptor forms a complex with lL-1 receptor accessory proteins including IL1 receptor-associated serine/threonine kinase (IRAK). IRAK becomes phosphorylated
and interacts with tumor necrosis factor receptor-associated protein (TRAF6), which has
been implicated in the activation o f NFkB (Kanakaraj et al., 1998). When IL -ip binds to
the Type 1 receptor cellular signaling begins (Spangelo, 1999; Dinarello, 1997). Signal
transduction for IL -ip is not fully understood. IL -ip has been shown to breakdown
phospholipids and increase arachidonic acid release via phospholipase Az activation
(O’Neill et al., 1995). IL -ip also increased lL-6 release and induced the hydrolysis o f
phosphatidylcholine by phospholipase Az in rat anterior pituitary cells in vitro (Spangelo
et al., 1991). Zumwalt and colleagues (1999) reported that IL -ip enhanced the release o f
EL-6 from rat C6 glioma cells. These investigators implicated lysophosphatidylcholine as
a second messenger leading to IL-6 release. Second messenger cascade signaling results
in the activation of mitogen-activated protein (MAP) kinases and tyrosine kinases that
lead to the activation o f transciption factors NFkB , jun-fos dimer A P I, and NF-1L6
(O’Neill, 1995; Bankers-Fulbright et al., 1996; Zumwalt et al., 1999).
lnterleukin-6 can function as a chemokine and an inflammatory cytokine.
IL-6 has a variety o f physiological and biological functions (Van Snick, 1990) including
B cell differentiation, T cell activation and proliferation, and induction o f the acute phase
response. Human DL-6 is a glycoprotein that has a molecular mass ranging from
21 -28 kDa depending on cellular source and preparation. The rat IL-6 amino acid
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sequence derived from peritoneal exudate cells (Northemann et al., 1989) is 93%
identical to murine lL-6 but only 58% identical to human IL-6. Unlike human lL-6 that
contains N- and 0-glycosylation, rat IL-6 lacks N-glycosylation sites.
lL-6 binds to a trimeric receptor consisting o f a glycoprotein a-subunit (gp80) and a
homodimer o f gpl30. It is the homodimerization o f the gpl30 unit upon lL-6 binding
that completes the trimeric receptor and triggers the Jak-Stat signaling cascade pathway
(Spangelo, 1999). Other cytokines and growth hormones also utilize this pathway. Jak
(Janus kinase) tyrosine kinases activated by crossphosphorylation subsequently
phosphorylate the receptor itself as well as the Stat (signal transducers and activators o f
transcription) proteins. The activated Stat proteins then homo- or heterodimerize and
translocate to the nucleus for transcriptional activation. In the case o f IL-6 binding, the
a-chain o f the receptor results in the dimerization o f gpl30 that in turn activates Jakl and
Jak2 tyrosine kinases to induce activation o f Statl and Stat3 proteins. The Statl and
StatS proteins enter the nucleus o f the cell as homo- or heterodimers, bind to DNA for the
synthesis o f mRNA and finally nascent protein (Spangelo, 1999). The IL-6 soluble
receptor (IL-6sr) is the soluble form o f the IL-6 receptor a-chain. IL-6 forms a complex
with the IL-6sr, which binds and signals through gpl30 inducing a response (Van
Wagoner et al., 1999).
IL -lp and T N F-a (Benveniste et al., 1990; Sparacio et al., 1992) induce lL-6 release
from astrocytes. The 5’ promoter region o f the EL-6 gene has three fimctional cisregulatory elements: the cyclic AMP-responsive, glucocorticoid responsive and multi
response elements. The multi-response element is activated by IL-1, TNF-a, senun,
phorbol esters (PMA) and IL-6 (Jones, 1994). Glial cells in the CNS are continually
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exposed to diverse neurotransmitters and neuropeptides. Norepinephrine (NE) and
isoproterenol (IPX; a P-adrenergic agonist) (Maimone et al., 1993; Zumwalt et al., 1998)
induce the release oflL -6 from astrocytes, and in the presence o f IL-1 P these agents have
a synergistic effect on lL-6 release. TN F-a and IL-ip in the presence o f lL-6sr also have
a synergistic effect on the production o f lL-6 from astrocytes (Van Wagoner et al., 1999).
Vasoactive intestinal peptide (VIP), a neuropeptide, also induces EL-6 secretion from
astrocytes (Maimone et al., 1993).
lL-6 has been implicated in a multitude o f neurodegenerative and inflammatory
diseases such as Alzheimer’s disease (AD)(Kalman et al., 1997) and rheumatoid arthritis
(Graeve et al., 1993). lL-6 is present in elevated concentrations in AD plaques, linking
this cytokine to pathological changes in AD (Hull et al., 1996).

Neurotransmitters: Monoamines
Neurotransmitters are compounds that are synthesized and released pre-synaptically
(Cooper et al., 1996). Specialized neurons are stimulated by an electrochemical signal
that results in the release o f chemical compounds from their storage sites within the cell
body into the synapse. The effects on the postsynaptic neuron can either be stimulatory
or inhibitory depending on the receptor present for the particular neurotransmitter.
Neurotransmitters can also have an effect on the surrounding glial cells.
Dopamine (DA), norepinephrine (NE) and epinephrine (E) belong to the
catecholamine neurotransmitter family (Figure 2) (reviewed in Cooper et al., 1996).
These neurotransmitters are released from catecholaminergic neurons. In the CNS,
dopamine represents about 50% o f the total catecholamines. Dopamine is found in
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discrete regions o f the brain including the nucleus accumbens, the neostriatum and the
tuberculum olfactorium. Norepinephrine distribution differs from that o f dopamine in
that it is more localized in the hypothalamus and generally found in gray matter more that
white matter. Epinephrine concentrations are low, 5%-17% o f NE content (Cooper et al.,
1996).
Catecholamines are formed in sympathetic nerves and ganglia from the amino acid
precursor tyrosine. The catecholamines are stored in granules within the nerve cell body
and upon stimulation the contents o f the granules are released by exocytosis. Once
released, the catecholamines recognize and bind to specific receptors on the plasma
membrane o f the adjacent neural cells. Depending on the receptor type, a signal
transduction occurs resulting in a cascade o f membrane and intracellular events. The
three classes o f receptors are a l , cc2 and P-adrenergic (P l, p2 subtypes). The adrenergic
receptor signals by coupling with G proteins (guanine nucleotide-binding regulatory
proteins). When the neurotransmitter binds to the select receptor, the receptor associates
with a G-protein to either stimulate or inhibit adenylyl cyclase activity by increasing or
decreasing the production o f cyclic adenosine monophosphate (cAMP). The Padrenergic receptors couple with the Gs protein thereby stimulating the adenylyl cyclase
cascade. The az-adrenergic receptors couple with G, protein and inhibits adenylyl
cyclase activity while ai-adrenergic receptor stimulates the phospholipase C activity
through a G protein still to be defined (Cooper et al., 1996). Figure 3 shows the proposed
mechanism for the activation o f adenylyl cyclase.
The catecholamines are just one type o f monoamine neurotransmitters. Another type
of monoamine neurotransmitters is the indoleamines (Cooper et al., 1996). Serotonin (5-
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hydroxytryptamine, 5-HT) is synthesized using the precursor amino acid tryptophan
(Figure 4). Serotonin is produced in other cells o f the body but is not able to cross the
blood-brain barrier. Therefore, the synthesis o f brain serotonin is dependent upon the
availability o f tryptophan. Tryptophan is taken in from the diet. Therefore dietary
protein content can influence brain tryptophan and serotonin levels. Metabolic products
of serotonin include 5-hydroxy indole acetic acid (5-HIAA) and N-acetyl serotonin. The
N-acetyl serotonin is converted to melatonin by the pineal enzyme 5-hydroxy indole Omethyl transferase. The pineal body is a gland (1 mg in the rat) in the dorsal surface o f
the hypothalamus. This gland contains all the enzymes required for the synthesis and
processing o f serotonin which is found in 50 times greater concentration (per gram) in the
pineal gland than in any other location. Serotonin is catabolized to melatonin in the
pineal gland. Environmental light and dark patterns affect the circadian rhythm o f both
melatonin and serotonin. Within minutes o f the dark cycle, the pineal gland p-adrenergic
receptors produce an increase in cAMP leading to activation of the N-acetyl transferase
resulting in synthesis o f melatonin (Cooper et al., 1996).
In the brain, serotonin-releasing neurons are found in the pons region, and the iq>per
brain stem. Serotonin neurons innervate the telencephalon and diencephalon by
projecting their axons along neural tracts to these regions. When stimulated, the neuronal
tracts release serotonin resulting mainly in inhibitory effects. There are multiple serotonin
receptors in the CNS including 5-HTia, i b .

id ,

5-HT2a.2b.2d, S-HTs, 5 -HT4 , 5-HT6, and 5-

HT7. The 5 -HT 3 receptors are ion-channel ligand-gated and are found only on neurons;

the rest o f the receptors are coupled to G-proteins (Table 1). When serotonin binds to the
selective receptor the following signal transductions may occur: 5-HT| receptor frunily
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has an inhibitory effect on adenylyl cyclase activity while 5 -HT 4 s, g 7 receptors have a
stimulatory effect resulting in an increase in cAMP production (Cooper et al., 1996).
5 -HT 2

receptor family is coupled to a G-protein that signals through phospholipase C

(PLC) leading to the production o f inositol triphosphate (IP3) and diacyl glycerol (DAG).

Role o f Cytokines in Inflammation and Neurodegeneration
Glial cells (neuroglia) consist o f macroglia (astrocytes and oligodendrocytes) and
microglia (macrophages). Astrocytes, the major glial cells in the CNS, are found in
regions o f axons, dendrites and in close contact with the surface o f neural blood vessels
(Cooper et al., 1996). Oligodendrocytes compose the myelin sheath that surroimds
axons. C6 cells, isolated from a chemically (N-nitrosomethylurea) induced rat brain
tiunor, are astrocyte-like cells that contain the protein S-100 (acidic protein soluble in 100
percent saturated ammonium sulfate at neutral pH; Benda, et al., 1968). C6 glioma cells
also have similar characteristics to the folliculostellate cells o f the anterior pituitary in
that both cell types are known to release IL-6 and contain the S-100 protein (Spangelo et
al., 1994; Tijerina et al., 1998). Another deflning component found in glial cells is the
glial fibrillary acidic protein (GFAP) which is often used as a marker for cell
homogeneity. Ilyin and colleagues (1999) demonstrated that when C6 cells are
introduced into the third ventricle o f the rat brain a tumor is formed o f astrocytic origin
(positive for GFAP and S-100 protein). The brain tumor formation results in increased
levels o f mRNA for IL-1 (3, IL-lra, IL-1 receptor Type I, and TNF-a in the cerebellum,
hippocampus, and hypothalamus.
Inflammation is a mechanism used to localize and concentrate an infection.
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Inflammation is a mechanism used to localize and concentrate an infection.
Increased blood flow to the infected area, capillary permeability to im m une cells, and the
migration o f leukocytes to the area o f the infection are all key events leading to
inflammation. Brain trauma can also elicit an inflammatory response. Brain trauma can
result from deprivation o f oxygen and nutrients, neurotoxic injury, viral infection or
immunological challenge. Brain inflam m ation results in gliosis characterized by the
activation, proliferation and hypertrophy o f mononuclear phagocytes (e.g., macrophages,
microglia) (Arvin et al., 1996). Specific cytokines (i.e., interleukin-ip, tumor necrosis
factor-a and interferon y) can exacerbate the brain damage. Cytokines activate glial cells
that in turn produce cytokines in response to the stimulation. The blood-brain barrier,
normally impermeable to immune cells o f the periphery, becomes leaky due to injury
allowing for peripheral T lymphocytes, natural killer cells and PMNs to contribute to
central inflammation. Brain inflammation can result in neuronal loss, edema formation
and the presence o f peripherally derived immune cells (Feuerstein et al., 1998).
Activated astrocytes and microglia may play a role in Alzheimer’s Disease (AD)
(reviewed in Mrak et al., 1995). Microglia are active in phagocytosis o f necrotic
material, and may be responsible for an alternative pathway of the cleavage o f P-amyloid
precursor protein (P-APP) that yields amyloid-type fiagments in AD. The activated
astrocytes express structural proteins such as GFAP, adhesion molecules, and S-IOOp (SlOOP is one o f two 10 kDa isoforms o f the S-100 protein). Activated astrocytes also
respond to IL-1 by producing IL-6, IL-8, TNF-a, and S-lOOp. In AD, activated
astrocytes form a "halo" around neuritic plaques.
Inflamatory mechanisms are evident in the pathogenesis o f Alzheimer’s Disease.
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Acute-phase proteins, such as al-antichymotrypsin and C-reactive protein, and activated
astroglia are found in patients with AD. IL- 6 is detectable in a significant proportion o f
plaques in patients with dementia (Hull, 1996). IL- 6 is also suspected in the regulation o f
the production o f APP. A single gene on chromosome 21, containing 19 exons o f which
three are alternatively spliced producing eight different isoforms, encodes the APP
protein. Patel and colleagues (1997) showed that deposition o f amyloid P-protein and an
increase in APP751 to APPggs ratio is evident in AD. The isoform Appzsi mRNA is
expressed in astrocytes while the isoform APPggg mRNA is mainly expressed in neurons.
Overexpression o f APPg9s does not induce neuropathological changes while
overexpression o f APP 7S1 and similar isoforms leads to progressive impairment in
leaming and memory. Ringheim and colleagues (1998) found that IL - 6 in the presence
IL-6 sr induces the P-APP promoter activity within 2 h followed by elevated levels o f PAPP. In addition, mRNA transcripts o f human brain tissue and cell cultures
demonstrated the presence of the alternatively spliced IL - 6 receptor mRNA, suggesting
the production o f IL-6 sr protein. They conclude that the IL-6 sr may enhance IL- 6 effects
on target cell populations resulting in increased P-APP expression in AD.
Cognitive impairment is a hallmark condition in AD. Heyser and colleagues (1997)
examined the cognitive functions o f transgenic mice that chronically expressed IL- 6 from
astrocytes. The transgenic mice were monitored over a period o f tim e ( 3 , 6 , and 12
months) regarding their ability to remember correct pathways through a Y-shaped maze
using footshock as a reinforcement. The avoidance response to footshock fell as the
transgenic mice aged indicating a potential alteration in brain pathophysiology due to
chronic expression o f IL-6 . The aged transgenic mice showed a marked increase in
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iininunostaîning for GFAP indicating an increase in microgliosis that m ay correspond to
avoidance leaming.
The cytokine IL-1 is an inflammatory mediator and has been implicated in the
progression o f neurodegeneration. Griffin and colleagues (1998) present a role for IL-1
and S-lOOp as key components in the cellular events leading to AD progression. This
group describes a cytokine-cycle due to the overexpression o f IL-1. Autocrine effects
can lead to IL-I stimulated glial cells, which in turn release IL-1 and EL-6. These
cytokines can each activate and increase the expression o f S-IOOP and the synthesis and
processing o f PAPP. The over expression o f cytokines and S-IOOP may result in
neurotoxic effects. Due to neuronal damage and loss resulting from the IL-I driven
events, microglia are further activated to increase the release o f IL-1 thus continuing the
cycle. Aging can result in a progressive increase o f IL-1 expression as well as S-lOOp.
The monoamine neurotransmitters N £ and serotonin are affected in patients with
AD. Neurons show evidence o f degeneration correlating with decreased levels of NE and
serotonin (McDonald et al., 1991). Bonaccorso and colleagues (1998) examined the
availability o f tryptophan in patients with AD. Results showed that in normal patients the
availability o f plasma tryptophan to the brain decreases with age and with the activation
o f the immune system (an increase in serum IL-6 was measured). Melatonin, a
metabolite o f serotonin has been shown to play a role in Parkinson’s Disease (Willis et
al., 1999). The administration o f melatonin, and its natural release, may exacerbate
Parkinson’s Disease raising a possible role for melatonin in movement disorders.
Oxidative stress is one recognized characteristic o f Parkinson’s Disease. Melatonin is a
known free radical scavenger with a reported 5-fold greater efficiency in neutralizing free
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radicals than the endogenous antioxidant GSH peroxidase (i.e. peroxide detoxification)
(Beyer et al., 1998). Thus, melatonin may provide a therapeutic role in reducing firee
radical tissue damage in disorders such as inflammation and neurodegenerative diseases.

Enzyme-Linked Immunosorbent Assay (ELISA)
Detection o f molecular species can be accomplished by two means; bioassays or
immunoassays. Bioassays are based on a biological activity while immunoassays are
based on immunological recognition. The use o f specific antibodies as reagents have led
to a growing field o f immimoassay based protocols (Gee et al., 1994). Because o f the
high afSnity o f antibodies for antigens, immunoassays are capable o f measuring
substances in complex matrices without extraction, purification or concentration. This
allows for a simplified procedure with the capability to process many samples in a short
period o f time (Edwards, 1996).
Immunoassays are analytical techniques that depend upon an antigen-antibody
reaction that is characterized by the Law o f Mass Action:
[Antibody + Antigen (free) <=>Antibody-Antigen (bound) Complex]
An immimoassay that involves the binding o f antigen to antibody followed by a physical
separation o f the bound antigen from the unbound antigen is a heterogeneous
immunoassay. A heterogeneous immunoassay requires a separation o f bound and free
reagent throughout the assay by washing the solid phase (e.g., wells o f a microtiter plate)
with a buffer containing a surfactant (e.g.. Tween 20). Homogeneous immunoassays do
not require a physical separation technique (e.g., fluorescent polarization immunoassay)
(Chan, 1987).
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An enzyme-linked immunosorbent assay (ELISA) is a common heterogeneous assay
format. The enzyme label can be detected by a variety o f methods, including the
absorbance o f a product measured colormetrically. The chromophore product is formed
enzymatically from a chromogenic substrate. Often the enzymatic reaction is terminated
with a stopping solution, such as sulfuric acid or hydrochloric acid. The chromophoric
absorption spectrum is changed with the stopping solution, and readings are made on a
microplate reader at an appropriate wavelength (Little, 1996). The enzyme horseradish
peroxidase (HRP) is a hydrogen-peroxidase oxidoreductase enzyme that transfers
hydrogen from hydrogen donors by the following reaction (Ngo, 1991):
HRP
HOOH + 2 Hydrogen Donor

2 H2O + 2 Oxidized Donor

The HRP activity is measured indirectly by the rate o f transformation o f the hydrogen
donor. TMB (3,3’,5,5’-tetramethybenzidine), in the presence o f HRP and hydrogen
peroxide, forms a one-electron oxidation product that is blue in color (653 nm
wavelength). When a stopping solution is added, the acid yields the diimine terminal
oxidation product that is yellow in color (450 nm).

Principle Hypotheses o f This Study
The development o f the novel lL-6 ELISA is based on previous work by Gee and
colleagues (1994). This ELISA format has been successful for detection o f
environmental compounds. The immunoassay design is based on the ability to coat the
wells o f a 96-well plate with an antigen (i.e., compound o f interest). The use o f a
primary antibody and an enzyme-labeled secondary antibody allows for the completion
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o f the immunoassay design. Upon addition o f the substrate, color development occurs
and is stopped by the addition o f an acid. The endpoint color development is then read at
a wavelength o f 450 nm. This ELISA procedure is applied to the development o f the
novel indirect lL-6 ELISA.
lL-6 plays a role in inflammation and neurodegeneration. The elucidation o f
mechanisms involved in the control o f the release o f lL-6 in the brain is an area o f
interest for developing therapeutic interventions. Catecholamines, especially
norepinephrine, act synergistically with IL -ip in stimulating th e release o f lL-6 from rat
C6 glioma cells in vitro (Zumwalt et al., 1999). lL-1 receptor antagonist has been
reported to inhibit IL-ip signal transduction by binding to the same lL-1 Type 1 receptor
(Dinarello, 1997). Serotonin, another monoamine, has been reported to increase lL-6
mRNA in rat hippocampal astrocytes (Pousset et al., 1996). M y research objectives in
this study are to first develop an lL-6 ELISA and secondly to identify the mechanisms
surrounding the release o f lL-6 from C6 glioma cells.
I . Development o f an indirect lL-6 ELISA
Ho The development o f an indirect ELISA is not achievable for the
measurement o f lL-6
Ha The development o f an indirect ELISA is achievable for the
measurement o f lL-6
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2. Effects o f lL - ip and IL -lra
Ho IL -1P and IL- Ira will not affect IL-6 release from C6 glioma cells
Ha IL -1P will have an affect on lL-6 release from C6 glioma cells
This effect will be prevented by the addition o f IL-lra
3. Effects o f Serotonin
Ho Serotonin will not effect lL-6 release from C6 glioma cells
Ha Serotonin will affect lL-6 release from C6 glioma cells
Serotonin and IL -lp will work synergistically on lL-6 release
4. Effects o f Melatonin
Ho Melatonin will not effect lL-6 release from C6 glioma cells
Ha Melatonin will affect lL-6 release from C6 glioma cells
Melatonin and IL -ip will work synergistically on lL-6 release
The development o f a novel ELISA for the detection o f lL-6 will be compared to the
existing 7TD1 bioassay currently used in our laboratory. The comparison will include
standard curves and assay sensitivities. The findings from the above investigations will
also help in the elucidation o f signal transduction pathways for the stimulation o f lL-6
release from rat C6 glioma cells thus providing further evidence o f the cytokineneuroendocrine role in inflammation and neurodegeneration.
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CHAPTER 2

MATERIALS AND METHODS

Chemicals and Reagents
(Bu^cAM P, p-mercaptoethanol, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyI
tétrazolium bromide), isopropanol (reagent grade), penicillin G, streptomycin sulfate,
gentamycin sulfate, melatonin, and serotonin were obtained from Sigma Chemical Co.
(St. Louis, MO). RPMI-1640, fetal calf serum (PCS), frmgizone, horse serum (HS), and
trypsin were obtained from Gibco (Grand Island, NY). Thymosin fraction 5 (TF5) was
generously provided by Dr. Allan L. Goldstein, George Washington University School o f
Medicine, Department o f Biochemistry and Molecular Biology (Washington, D C ) .
Recombinant rat IL -ip (IL-IP) was obtained from PeproTech Inc. (Rocky Hill, NJ).
Recombinant murine lL-6 (rmIL-6), recombinant human lL-1 receptor antagonist (ILlra), and recombinant human EL-6 soluble receptor (lL-6sr) were obtained from R & D
Systems (Minneapolis, MN). Dr. J. Van Snick, Ludwig Institute (Brussels, Belgium),
generously provided the 7TD1 hybridoma cell line. The C6 glioma cell line was obtained
from the American Tissue Type Culture Collection (Rockville, MD).

C6 Glioma Cell Culture
C6 glioma cells were maintained in continuous culture in a humidified atmosphere o f
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5% C02-95% air at 37 “C in complete RPMI-1640. Complete RPMI-1640 inlcudes 7.5%
horse serum (HS), 2.5% fetal calf serum (PCS) and antibiotics (7.5 pg/mL streptomycin,
15 pg/mL gentamycin, 19 pg/mL penicillin, 0.6 ^ig/mL fungizone). After 2-3 days in
culture, cells were removed from the tissue culture flasks with 0.25% trypsin in
phosphate-buffered saline, resuspended in serum-free RPMI-1640, and counted by
hemacytometer. The cells were then either placed in continuous culture (1.0 x 10^ cells
per 25 cm" flask, Greiner) or were dispersed into 12-well tissue culture plates (800 x 10^
cells/well, Palcon) for the measurement o f lL-6 using the ELISA assay. C6 cells were
also dispersed into 96-well tissue culture plates (Greiner) at 100 x 10^ cells/well with
complete RPMI-1640 for the measurement o f lL-6 using the 7TD1 bioassay.
Por ELISA experiments, the cells were allowed to adhere for 24 h, rinsed twice with
serum-free RPMI-1640 medium (sfRPMl), and then incubated for 24 h with vehicle
(sfRPMl), or 1% complete RPMI-1640, in the absence or presence o f 500 ng/mL TP5 (1
mL per well). Conditioned media was removed and stored at 4 °C pending analysis for
lL-6 by ELISA.
For 7TD1 bioassay experiments, the cells were allowed to adhere for
24 h, rinsed twice with sfRPMl, and then incubated for 24 h with vehicle (sfRPMl) in the
absence or presence o f IL-ip, monoamines, or other agents (200 pL per well). In some
experiments, C6 cells were pretreated with IL-lra for 30 min or monoamines for 10 min
in sfRPMl medium and subsequently exposed to the compounds o f interest in the absence
or presence o f 1L-1(3. Conditioned media was removed and stored at 4 °C pending
analysis for lL-6 by bioassay.
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ELISA Reagents
Recombinant rat IL-6 and polyclonal rabbit anti-rat lL-6 were obtained from
Antigenix America (Franklin Square, New York). Goat anti rabbit IgG horseradish
peroxidase (HRP) enzyme conjugate and 3,3’,5,5’-tetramethybenzidine (TMB) hydrogen
peroxide enzyme substrate solution were obtained from Chemicon International, Inc.
(Temecula, CA). Tween 20 was obtained from Sigma Chemical Co. (St. Louis, MO).

ELISA Instrumentation and Equipment
Nunc-lmmuno MaxiSorp Surface microplates were used for all ELISA procedures
(Nalge Nunc International, Denmark). ELISA absorbances were read in the end point
mode (450 nm) with a Dynatech MR5000 plate reader (Dynex Technologies, the new
Dynatech Laboratories, Chantilly, VA).

Optimization o f ELISA Procedure
The optimization o f the ELISA procedure for the detection o f IL-6 and the indirect
ELISA format was accomplished by adapting an immunoassay technique from the U. S.
Environmental Protection Agency (Gee et al., 1994). Antigen-coated plates were
achieved by passive absorbance o f the lL-6 antigen to the Maxisorb plate surface. A
solution o f coating antigen (CoAg) in carbonate coating buffer (0.1 M NaHCOg, pH 8.2)
was added to a plate (150 pL/well). The CoAg was prepared with lL-6 and the dilutions
typically ranged from 6 ng/well to 0.094 ng/well. Each dilution was added to one o f the
twelve columns o f the plate (one dilution/column). The plate was covered with acetate
sealer tape, and stored overnight at 4 °C.
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On the following day, the plate was washed three times with 200 pL o f phosphate
buffered saline with 0.1% Tween-20 (PBST). The rabbit anti-IL-6 antibody was serially
diluted 1:500 to 1:6400 in PBST and 150 pL was added to one o f the eight rows o f the
washed plate (one dilution/row). The plate was sealed and incubated at ambient
temperature for 3 h and then washed as before. Goat anti-rabbit IgG HRP conjugated
antibody (1:5000) was added (150 piL/well), and the plate was covered for a 2 h
incubation (ambient temperature). After washing as before, 100 pL o f the TMB enzyme
substrate solution was added to the wells for seven to ten minutes o f color development.
A stopping solution o f 0.25 M HCl was added (100 ^L/well) resulting in a color change
that was read within five min at 450 nm on the plate reader.

ELlSA-lndirect Format
Day O ne: The coating antigen was prepared with 3 ng/well o f lL-6 as determined by
the reagent optimization assays. The plate was covered with sealer tape, and stored
overnight at 4 °C. On the same day, lL-6 standards were diluted in PBST and 300 jiL o f
each standard was added to 12 x 75 mm polystyrene plastic tubes typically ranging from
100 ng/mL to 0.25 ng/mL (including a zero standard). The glial cell condition medium
was also added to plastic tubes (300 pL/tube). Rabbit anti-lL-6 antibody was diluted
1:750 and 300 \iL o f this solution was added to the tubes containing IL-6 standards and
samples resulting in a final antibody dilution o f 1:1500 (as determined by reagent
optimization assays). The tubes containing these incubation solutions were sealed, and
the antibody was allowed to react with the IL-6 overnight at ambient temperature.
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Day Two: The IL-6 antigen-coated plates were washed three times w ith PBST (200
pL/well). The pre-incubated solutions from day one were added to the antigen-coated
plates in triplicate (150 fxL/well) and allowed to incubate, covered, for 3 h at 21 “C. After
washing the plates again with PBST, 150 pL o f a solution in PBST o f goat anti-rabbit
IgG labeled with HRP enzyme conjugate (1:5000 dilution) was added to each well.
Plates were covered, incubated for 2 h a t 21 °C, and washed for a final time with PBST.
100 pL o f the enzyme substrate TMB solution was added to each well for seven to ten
minutes allowing for color development. A stopping solution o f 0.25 M HCl was added
( 100 pL) to the wells resulting in a color change that was read at 450 nm within 5 min
using the plate reader. A general schematic o f the ELISA procedure is outlined in
Figure 5.

ELISA Data Handling
Construction o f a calibration curve is based on a four-parameter logistic equation
that results in a monotonie, smooth continuous curve. The four-parameter logistic
equation is defined by
y = ((A - D)/ (1 + (x/C)®l + D
where y is the absorbance, x is the concentration o f antigen, A and D are the upper and
lower asymptotes respectively, B is the slope and C is the central point on the linear
region o f the curve termed as the ICso (Figure 6). At least 6 standard curve points are
used with this model (two more calibrator points than the number o f parameters
estimated). The ICso values are calculated based on the four-parameter curve logistic fit
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using SOFTmax PRO Version 2.1.1 software (Molecular Devices Inc., Palo Alto, CA).
Data are presented as the mean ± standard error o f the mean (SEM) consisting o f 3 to 4
observations per experimental group.

7TD1 Bioassay for IL-6
The accumulation o f IL-6 in the C6 glioma cell conditioned media was quantified
using the IL-6-dependent 7TD1 hybridoma bioassay as previously described (MacLeod et
al., 1993), with minor modifications. This particular IL-6 sensitive hybridoma has not
responded to a variety o f cytokines or hormones including IL-1, interferon-a and ~P,
tumor necrosis factor (TNF)-<x, prolactin (PRL), or growth hormone (GH) (Spangelo,
1990). The 7TD1 cells were maintained in continuous culture in a humidified
atmosphere o f 5% COz-95% air at 37 °C in 10 mL RPMI-1640 supplemented with 5%
FCI (Fetal Clone I; Hyclone, Logan, UT), 50 pM P-mercaptoethanol, 5 pg/mL rmIL-6,
and antibiotics. Approximately 400 x 10^ 7TD1 cells were distributed in a 25 cm^ flask
(Greiner) for continuous culture. Conditioned medium (20 pL) was cultured in 96-welI
tissue culture plates in duplicate for 72 h in the presence o f 4,000 7TD1 cells/well in 200
pL o f RPMI-1640 supplemented with 5% FCI, 50 pM P-mercaptoethanol, and
antibiotics. The extent o f 7TDI proliferation was determined using the tétrazolium salt
MTT, which is cleaved in active mitochondria to form a dark blue formazan product.
After a 72 h incubation period, 20 pL o f 5 mg/mL MTT was added to each well for 4 h.
Following removal o f 150 pL medium firom each well, the dark blue crystals were
dissolved by the addition o f 150 pL o f 0.04 M HCl/isopropanol. After an overnight
incubation in the dark, optical densities were obtained in a microelisa instrument using a
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test wavelength o f 570 nm and a reference wavelength o f 630 nm (Dynatech MR5000) or
the Spectra Max Plus plate reader (Molecular Devices Inc., Palo Alto, CA). An empty
96-well plate was used to zero the microelisa machine. A standard curve o f rmIL-6
(0.125-16.0 pg/well) was generated in each assay. Data are presented as the mean ± SEM
consisting o f 3 to 4 observations per experimental group.
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CHAPTERS

RESULTS

Optimization o f ELISA
A two dimensional titration (i.e., checkerboard titration) is designed to test two
reagents simultaneously. The rat IL-6 antigen and the rabbit anti-rat IL-6 antibody were
not specifically designed to work together in an ELISA format. A checkerboard titration
will determine the titer o f the reagent and the dilution required to give a reasonable signal
for the antigen and anti-antigen antibody. Data analysis o f the checkerboard is achieved
by plotting the absorbance against the concentration o f the coating antigen for each
antibody dilution. A family o f curves is obtained (Figures 7 and 8) such that the
absorbance increases linearly for any one curve until reaching saturation. The coating
antigen (CoAg) concentration is determined based on the concentration at which the
absorbance no longer increases. In Figure 8, the CoAg concentration o f 3 ng is enough to
trap all antibodies added to the well. The antibody dilution o f 1:1500 for the above CoAg
concentration gives a reasonable absorbance between 0.5 and 1.5.
Alternatively, the checkerboard data can be analyzed by plotting the absorbance
against the antibody concentrations for each concentration o f CoAg (Figures 9 and 10).
The family o f curves shows that the absorbance declines as the antibody concentration
decreases. A steep slope between two antibody dilutions is optimal. Therefore a small
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change in bound antibody would result in a significant change in absorbance. In Figure
10, the steepest slopes are found in the 1:1000 and 1:2000 antibody range. The 3 ng/well
IL-6 CoAg has a fairly steep slope in the optimal antibody range. Therefore, from
Figures 8 and 10, a CoAg concentration o f 3 ng/well and an antibody dilution o f 1:1500
were used for ELISA reagent optimization.

ELISA Standard Curve
The generation o f a reproducible standard curve is imperative to developing a
consistent ELISA method. Plotting the absorbance against the logio o f IL-6
concentrations generates the standard curve. The IL-6 standards provide a complete
definition o f the curve that is sigmoidal in shape (2 to 3 points defining the upper and
lower asymptote and at least 4 points defining the linear region). Figure 11 shows the
four-parameter logistic calibration curve with an ICso o f 3.1 ng/mL IL-6, a concentration
corresponding to 50% binding. Absorbance values that fall on the linear portion o f the
calibration curve (between 1 and 10 ng/mL) are ideal for calculating IL-6 concentrations
in unknown samples. Absorbance values that fall on the upper or lower asymptotes are
considered out o f the calibration curve range o f detection. The limit o f detection for this
standard curve is 0.25 ng/mL. The limit o f detection was determined by identifying the
lowest concentration o f antigen which can be distinguished from zero and then
multiplying the standard deviation by three (Howes, 1996).
The standard curve was generated using PBST as the matrix for dilutions o f IL-6
antigen and o f the rabbit anti-rat IL-6 antibody. C6 cells were subjected to 50-500 pg/mL
TF5, a known stimulator o f IL-6 release from C6 cells (Tijerina et al., 1998). IL-6 in
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these samples was not detectable on the ELISA IL-6 standard curve because values were
in the upper asymptote range o f the standard curve (data not shown). The C6 conditioned
medium consists o f serum-free RPMI (sfRPMl) and other components released during
the 24 h incubation period which might affect antibody-antigen binding capabilities. To
test this possible matrix interference, IL-6 standard curves were generated comparing
PBST, sfRPMl and 1% complete RPMI (i.e., complete RPMI is diluted 1:10) matrices
(Figure 12). The 1% complete RPMI standard curve has a decreased detection range
compared to the sfRPMl and PBST curves with IC50 values o f 4.89, 5.41 and 5.54
respectively. The shifting o f the standard curve to the left allows for increased sensitivity
(i.e., lower ICso) but results in decreased resolution o f the points on the curve (i.e., curve
becomes less steep). In Figure 12, the standard curves for the different matrices do not
result in a noticeable left shift leading to increased sensitivity. IL-6 presumably released
from C6 cells treated with TF5 (500 pg/mL) was not detectable in any o f the above
standard curves. Therefore, sfRPMl or 1% complete RPMI does not interfere with the
ELISA format. Thus, the indirect ELISA format is not sensitive enough to detect IL-6
present in the conditioned medium samples.

7TD1 Bioassay Standard Curve
Representative bioassay standard curves are shown in Figures 13 and 14. The dose
response curve obtained from the relationship between nnIL-6 concentrations and optical
density approximates a line-of-best-fit equation. In Figure 13, the line-of-best fit is a
linear regression equation where amounts o f rmIL-6 greater than 8.0 pg/well do not
provide further linear increases in optical density values; thus, samples need to be diluted
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properly to generate values in the linear portion o f the standard curve. A correlation
coefficient o f >0.99 is obtained, and the linear regression equation is easily solved for xaxis values. The limit o f detection as determined by three times the standard deviation o f
a concentration that is not zero (Howes, 1996) for IL-6 in this assay is 5 pg/mL.
In some cases the linear regression equation is not the best fit for the standard
points given. A logarithmic line-of-best fit equation generates a curve that better
approximates the standard points in Figure 14. The logarithmic equation allows for
values o f IL-6 to be calculated only on the linear portion o f the curve. Therefore,
appropriate dilutions o f the samples are necessary for values to fall on the dynamic range
o f the logarithmic curve. The correlation coefficient o f >0.96 is obtained and the
logarithmic equation is easily solved for x-axis values. In this assay the limit o f
detection, as defined by Howes (1996), for IL-6 is 2 pg/mL. Depending on the standard
points, the line-of-best-fit is discretely determined to allow for optimal IL-6
concentrations to be resolved. O f the two equations, the linear regression model is used
more often to define the best-of-line fit for the points generated from the rmIL-6 standard
curve. Table 2 compares the IL-6 ELISA standard curve to the 7TDI standards curves.

Rat Interleukin-ip Time Course and Dose Response
Rat IL-1 p increased the release o f IL-6 in a concentration and time-dependent
maimer (Figure 15). The basal release o f IL-6 firom C6 cells was undetectable under 12 h
o f incubation. After 12 h o f incubation there is a steady basal increase o f IL-6 resulting
in a 12.4-fold increase at 48 h in comparison to 12 h. The baseline detection o f IL-6
results fi’om the amount o f IL-6 release firom the C6 cells cultured in sfRPMl medium at
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each tim e point. Therefore, the increase in the baseline is a time-dependent event. The
concentration response showed that 5 -1 0 0 ng/mL IL -ip generated similar increases in
IL-6 release at all time points. A concentration o f 50 ng/mL IL -ip at the 24 h incubation
period was used for all subsequent experiments (Figure 16). The increase in IL-6 release
from C6 cells was maximal between 5 and 100 ng/mL IL -ip.
Effects o f Rat Interleukin-1 Receptor Antagonist
IL -lra binds to both Type I and Type H IL-1 receptors thereby preventing IL -lp
from binding and transducing a signal. IL -ip (10 and 50 ng/mL) stimulated IL-6 release
(83.5 db 10 pg/well and 165 ± 24 pg/well, respectively) (Figure 17). hi the presence o f ILlra (100 ng/mL), IL-6 release was reduced in half (41.5 ± 5 pg/well) in the presence o f
10 ng/mL IL -ip and by a third (58.1 ± 2.6 pg/well) in the presence o f 50 ng/mL EL-ip.
As controls, the vehicle (sfRPMl) and IL -lra (100 ng/mL) resulted in only basal release
of IL-6 (21.7 ± 2.2 and 25.6 ± 3.0 pg/well, respectively). Therefore, IL-ip stimulation o f
the IL-6 release from C6 glioma cells is a receptor mediated event.

Effects o f Serotonin, Melatonin and IL -ip on IL-6 Release
O ur laboratory recently showed that IL -lp and norepinephrine have a synergistic
effect on the release o f IL-6 from C6 glioma cells in vitro (Zumwalt et al., 1999). We
decided to investigate serotonin, another monoamine, for possible synergism with IL -ip
in releasing IL-6 from C6 cells in vitro. As shown in Figure 18, serotonin (0.5 to
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100 pM) did not affect the basal release o f IL-6. IL -ip (50 ng/mL) stimulated IL-6
release to 144 ± 3.3 pg/well. When IL -ip was combined with varying amounts of
serotonin no further induction o f IL-6 occurred.
To further test if serotonin had any synergism with IL -ip for IL-6 release,
concentrations o f serotonin were reduced to the nM range (Figure 19). The
concentrations were reduced due to the findings by Pousset and colleagues (1996) who
demonstrated that maximal IL-6 mRNA was stimulated by serotonin the nM range.
Serotonin (1 to 100 nM) was incubated by itself or with IL -ip (10 and 50 ng/mL).
Isoproterenol (IPT) served as a positive control for P-adrenergic receptor synergistic
enhancement o f IL-6 release. IPT, a P-adrenergic receptor agonist, activates adenylyl
cyclase to increase cAMP concentrations. Figure 19 shows that indeed IPT (10 pM) in
the presence o f IL-ip (10 and 50 ng/mL) resulted in a 3-fold induction o f EL-6 release
from C6 cells. For example, IL -ip (50 ng/mL) increased IL-6 release to 115 ± 10
pg/well and, while in the presence o f IPT, IL -ip synergistically increased IL-6 release
345 ± 24 pg/well. Serotonin only resulted in the basal release o f IL-6 in comparison to
vehicle (srRPMI, 21 ± 3 pg/well IL-6). In the presence o f IL-1 P, serotonin had no
synergistic effects.
Melatonin, a product o f serotonin breakdown (Figure 4), was also examined for
potential synergism with EL-ip on IL-6 release from C6 cells. Melatonin (I to 100 nM)
had no effect on the basal release o f IL-6 (Figure 20). IL -ip (10 and 50 ng/mL) and
melatonin showed no synergistic ability in releasing IL-6 in comparison to the positive
control (IPT).
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Effects o f Serum Containing RPMI-1640
Varying amounts o f diluted complete RPMI and IL -ip were investigated for their
potential to increase EL-6 release. IL -ip (0.5 to 100 ng/mL) was incubated with sffUPMI,
0.1%, 1% and complete RPMI (i.e., 0.1% and 1% are dilutions o f the complete RPMI)
(Figure 21). Increasing amounts o f serum resulted in the increased release o f IL-6.
Exposure to IL-1 P (10 ng/mL) resulted in 74, 176, 223, and 235 pg/well IL-6 in sfRPMl,
0.1%, 1.0%, and complete RPMI, respectively. This increased induction o f IL-6 when
combining IL -ip and 0.1% complete RPMI was further investigated. The presence o f
serum in the experiment may allow for enhanced binding for serotonin. Serotonin (0.5 to
100 pM) was incubated with IL-ip (50 ng/mL) in 0.1% complete RPMI (Figure 22). ILip (50 ng/mL) stimulated the release o f IL-6 in 0.1% complete RPMI (178 ± 18 pg/well).
In addition, serotonin had no synergistic effect when incubated in the presence o f IL-1 p.
Therefore, the use o f 0.1% complete RPMI did not enhance serotonin binding in
increasing IL-6 release by itself or in the presence o f IL-1 p.
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CHAPTER 4

DISCUSSION
Indirect IL-6 ELISA
The development o f an indirect competitive IL-6 ELISA resulted in an assay with a
detection range from 1 to 10 ng/mL and an IC 50 o f 3.1 ng/mL IL-6 (Figure 11). ELISAs
in general are multicomponent assays that require careful selection o f reagents, buffers,
and test parameters to ensure a precise and sensitive assay. The antibody affinity for
antigen is an important characteristic for assay sensitivity. If the antibody has too high o f
an affinity for the coating antigen than for the antigen o f interest, an equilibrium shift
may occur thereby reducing assay sensitivify. The anti-rat IL-6 antibody that incubates
with EL-6 overnight may also have an equal affinity for the coating antigen (i.e., IL-6
covalently bound to wells). Different vendors offer paired antibody-antigen sets that
have been optimized to work together in an immunoassay format. An example o f these
paired antibody-antigen sets is ELISA kits. IL-6 ELISA kits for murine IL-6 (Wang et
al., 1999) and human IL-6 (Loret De Mola et al., 1996) have the ability to detect 15
pg/mL and 2 pg/mL, respectively. The anti-rat IL-6 antibody and the IL-6 antigen were
purchased from the same vendor, but they were not offered as a paired set. In using the
rat IL-6 protein as the coating antigen and in the standard curve, the anti-rat IL-6
antibody was recognizing the same antigen (i.e., IL-6 coated to the surface o f the plate
and IL-6 in the standards). Therefore, reducing the range o f detection from nanograms to
33
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picograms may not be successful due to the high affinity binding o f the antibody to the
IL-6 antigen.
The antigen coating to the surface o f wells can be influenced by the solid phase itself
(e.g., polystyrene, polyvinyl chloride), buffer conditions (i.e., pH, %Tween), and by time
and temperature (Voiler et al., 1986). IL-6 is a 26 kDa protein that is passively absorbed
through non-covalent interactions onto the polystyrene plastic wells. A carbonate coating
buffer with an alkaline pH is recommended for most protein absorbtions. Coating buffers
with pH o f 8.6 and 9.6 were tested on coating IL-6 to the plates resulting in no difference
in standard curves (data not shown). A neutral pH is optimal for the phosphate buffered
saline with Tween-20. A phosphate buffered saline with 0.1% Tween-20 (pH 7.4) was
used in the IL-6 ELISA. The Tween-20 helps to reduce non-specific binding o f reagents.
Non-specific binding (NSB) is the measure o f the HRP-labeled antibody that is not bound
to anti-rat IL-6 antibody (i.e., the HRP-labeled antibody binds to non-coated portions of
the plastic well). The addition of Tween-20 during the incubation and washing steps of
the ELISA aids in the reduction o f NSB. Another method to prevent NSB is to block the
coated plate. We examined this possibility using bovine serum albumin (BSA). After
coating the IL-6 to the surface o f the plate (incubation at 4'*C overnight) the plate was
washed and then blocked with a 1% BSA (mixed in PBST) for a 1 h incubation period.
The blocking o f the wells prior to addition o f the standards did not result in increased
sensitivity o f the developed ELISA (data not shown).
In troubleshooting the parameters o f the developed assay, guidelines given by Gee
and colleagues (1994) were followed: hi cases o f low color development the problem is
most likely due to decreased enzyme activity, incubation temperature, and possible
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matrix effects. For testing the enzyme activity, increased concentrations (2-5 times) of
the HRP-labeled antibody were added to the substrate solution (1:5000 dilution) and
incubated for 2 h. In this instance, the color development was similar to that obtained in
the assay. Therefore, both the enzyme-labeled antibody and substrate solution were not
the cause for decreased color (data not shown). Incubation temperatures were kept
consistent (4°C for the overnight coating step and ambient temperature for the rest o f the
ELISA steps) and were not suspected for possible loss in color development. Matrix
effects (Figure 12) showed that the use o f PBST, sfRPMl, and 1% complete RPMI did
not greatly affect assay conditions. The sfRPMl curve was parallel to the PBST with
similar ICso values (5.41 and 5.54 ng/mL IL-6). The 1% complete RPMI standard curve
showed a decreased range o f detection by one-half order o f magnitude. Unknown
samples would need to fall in the linear portion of either the PBST or sfRPMl standard
curves for accurate measurement o f IL-6. The IL-6 ELISA was not sensitive enough to
detect any released IL-6 in the condition medium in which the C6 cells were subjected to
500 Pg/mL TF5. In previous experiments using the 7TD1 bioassay, TF5 (100 pg/mL)
was shown to increase the release o f IL-6 from C6 cells (Tijerina et al., 1998). In
comparing the bioassay to the ELISA, the bioassay can detect picogram amounts o f IL-6
bioactivity while the developed ELISA is unable to detect IL-6 from conditioned medium
immunologically (Table 2). The 7TD1 bioassay is a more sensitive assay for detecting
EL-6 (pg/well). This assay was used for the remainder o f the experiments.
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Effects o f IL-1 p and IL-lra on IL-6 Release
IL-1 P has been shown to stimulate the release o f IL-6 in the human astrocytoma
cell line U373 (Lieb et al., 1996) and in the rat C6 glioma cell line (Zumwalt et al., 1999).
Indeed, rat IL -ip stimulated IL-6 release from rat C6 cells in vitro (Figure 16). The
release o f IL-6 can be detected over a period o f time (Figure 15) o f which a considerable
amount was released during the 24 to 48 h incubation. IL-ip binds to the IL-1 Type I
receptor allowing for signal transduction. The exact cascade o f intracellular events has
yet to be elucidated. Some second messengers that may be involved in signal
transduction include the G-proteins, cAMP-dependent serine/theronine kinases (PKA),
protein kinase C (PKC), and lipid metabolism or mediators (Bankers-FuUbright et al.,
1996). Type I receptor mRNA is expressed in astrocytes (Tomozawa et al., 1995)
confirming that IL -ip stimulation o f IL-6 release is receptor mediated. IL -lra blocks
signal transducing events by binding to the IL-1 Type I receptor thereby preventing IL -ip
from binding (Figure 17). Further experiments will include different concentrations o f
IL -lra to find the optimum concentration for blocking IL-6 release in the presence o f ILip . The presence o f IL -lra may serve as a defense mechanism to m in im ize the proinflammatory response o f IL-1 p and IL-6. Bresnihan and colleagues (1998) reported the
therapeutic affects o f using IL -lra (150 mg/day) for treating iheumatoid arthritis. IL-lra
has also been suggested for blocking IL-1 effects in patients with glomerulonephritis
(Nikolic-Paterson et al., 1996).
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Effects o f Serotonin and Melatonin on IL-6 Release
IL-1 p has been shown to act synergistically with TNF-a in stimulating IL-6 release
from astrocytes (Maimone et al., 1993; Gayle et al., 1998). Norepinephrine and IL-P also
work synergistically in releasing IL-6 from astrocytes (Maimone et al., 1993; Zumwalt et
al. 1999). The monoamines DA, NE, and E were shown to act synergistically, NE having
the greatest effect, with IL -lp by stimulating IL-6 release from rat C6 cells (Zumwalt et
al., 1999). Serotonin, another monoamine, did not show synergism with IL -ip on
stimulating IL-6 release from rat C6 cells (Figure 18). Serotonin (10^ to 10"'^) can
increase IL-6 mRNA expression in rat astrocytes (Pousset et al., 1996). The pM
concentration o f serotonin (Figure 17) was reduced to concentrations in the nM range as
described by Pousset and investigators (1996) (Figure 19) Wiich again had no synergistic
effect in the presence o f IL-1 P in releasing IL-6. NE binds to the P-adrenergic receptor
and stimulates the production o f cAMP. IPT, a p-adrenergic agonist, was used as a
positive marker by synergistically acting with IL -ip on stimulating the release o f IL-6
(Figures 19 and 20). Melatonin, a product o f serotonin metabolism, did not have a
synergistic effect with IL -ip on releasing IL-6 from C6 cells (Figure 20). IL -ip
incubated in 0.1% complete RPMI stimulated IL-6 release 3-fold compared to sfRPMl
(Figure 21 ). Serotonin and IL -lp were incubated in 0.1% complete RPMI on the C6 cells
(Figure 22) which again had no synergistic effect on releasing IL-6 from C6 cells. IL -ip
stimulated the release o f IL-6 from astrocytes but not in a synergistic maimer with the
monoamine serotonin, or its metabolite, melatonin.
Serotonin can bind to a variety o f receptors (Table 1) o f which 5 -HT 2 receptor is
predominantly found on astrocytes (Hansson et al., 1987). The S-HT2 receptor is linked
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to the breakdown o f inositol phospholipid resulting in inositol monophosphate and
diacylglycerol. In the above studies, serotonin may be binding to S-HTz receptors, which
is not synergistically linked to the IL-1 p signal transduction pathway. Further
investigations will be designed to identify if the presence o f serotonin has inhibitory
effects on IL-6 release. Serotonin will be incubated in the presence o f IL-1 p and IPT.
Present results showed that IPT and IL -lp have a synergistic effect on IL-6 release, in the
presence o f serotonin, this synergistic response may be reduced.
In the study by Pousset and colleagues (1996) serotonin increased IL-6 mRNA
within I hour o f incubation but the IL-6 protein was not concomitantly measured. The
induction o f IL-6 mRNA and protein release would be an area for further investigation.
One way to determine i f intracellular IL-6 is present in the cell would be to harvest the
cells and then perform cell lysis. Intracellular IL-6 concentration could be measured
using the 7TD1 bioassay.

Role o f IL-6 and IL-6 Receptors in Neurodegeneration
IL-6sr is another area for further investigation. IL-6sr binds IL-6 and then signals
through the gp 130 membrane bound receptor. Glial cells express IL-6 receptor mRNA
that can be alternatively spliced to form soluble IL-6 receptor (Van Wagoner et al.,
1999). The gpI30 receptor unit can be found in different regions o f the brain since other
hormones can associate with this particular unit. The increased amounts o f IL-6sr allows
for IL-6 to bind to gpI30 units in different parts o f the brain other than were the classical
IL-6 membrane bound receptor would be found. Thus, the IL-6sr may enhance the
overall function o f IL-6 to otherwise non-responsive cell types and to regions o f the brain
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distant from the original site o f IL-6 production (Ringheim et al., 1998). Harrison and
colleagues (1996) demonstrated that monoclonal antibodies for gpI30 could inhibit the
production o f acute phase reactants. IL-6 induces a systemic acute-phase response
resulting in fever, and increased fibrinogen, C-reactive protein and platelet count. The
use o f anti-gpI30 antibodies may present another role for developing treatments for
inflammatory conditions.
Circulating levels o f IL-6sr are under investigation for their potential role in AD.
Angelis and colleagues (1998) measured serum levels o f IL-6sr in AD patients and found
a reduction suggesting a dysregulation of IL-6sr and IL-6 in AD. A decrease in IL-6sr
was also found in the cerebrospinal fluid of AD patients (Hampel et al., 1998). The ratio
o f EL-6:EL-6 receptor;IL-6sr is 1:1000:60000 with IL-6 having low affinity to IL-6
receptor and a higher affinity to IL-6sr and the gpl30 unit. Marz and colleagues (1997)
found cerebrospinal fluid levels o f IL-6, IL-6sr and gpl30 unchanged in patients with
AD, but these levels do not reflect potential alterations o f the IL-6 receptor system in
specific brain regions o f AD. The link between IL-6, IL-6sr and the membrane bound
pgI30 receptor unit are still under investigation for their effects in AD.
W ith the evidence o f the potential role IL-6 plays in the in flam m ato ry and

neurodegenerative processes, the elucidation o f its activation and release are pertinent for
developing therapeutic interventions. IL-6 levels are increased in Alzheimer's Disease
(Hull et al., 1996; Mrak, et al., 1995), Parkinson's disease, AlD's related dementia. Down
syndrome dementia (Kalman et al., 1997), autoimmune disorders (Graeve et al., 1993)
and ovarian hyperstimulation syndrome (Loret De Mola et al., 1996). The release o f IL-6
from activated glial cells may be responsible for the cleaveage o f the P-amyloid precursor
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protein resulting in the amyloid fragments found in AD. In particular, the am yloid
precursor protein isoform 751 may play an important role in the progressive imp a irm e n t
in learning and memory (Mrak et al., 1995; Patel et al., 1997). Changes in
catecholamines and catecholaminergic neurotransmission are known in AD. The
synergistic mechanism o f ME and IL-1(3 on releasing IL-6 from glial cells is one way
catecholamines can modulate immunological responses in the brain. Alterations in
serotonin metabolism may also play a role in AD. Bonaccorso and colleagues (1998)
reported a correlation between levels o f tryptophan, precursor to serotonin, and an
increase in serum IL-6 from elderly patients with AD. From the above experiments,
serotonin directly increasing the release o f lL-6 was not foimd in the C6 glioma cells
(Figures 18 and 19).

Conclusion
The development o f a sensitive, reliable lL-6 ELISA was attempted in this study.
The LOD for lL-6 was 0.25 ng/mL with a detection range o f 1-10 ng/mL. Therefore, 1
reject the null hypothesis and accept the alternative hypothesis for the development o f the
EL-6 ELISA. Due to the lack in sensitivity for IL-6 measurement in comparison to the

7TD1 bioassay, the ELISA was not chosen as the detection method. The 7TD1 bioassay
LOD for EL-6 was 2-5 pg/mL and therefore was implemented as the detection method for
measuring IL-6 in the experiments described in this study.
There is strong evidence for cytokines in the promulgation o f inflam m ato ry and
neurodegenerative diseases. EL-ip and IL-6 are found to be principle cytokines in
exacerbating acute phase immune response. IL -ip, by itself or synergistically with
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catecholamines, activates glial cells to release EL-6. EL-Ira inhibits the release o f IL-6
providing a potential therapeutic model. From these results, I reject the null hypothesis
and accept the alternative hypothesis stating the effects o f IL -ip increased the release o f
IL-6 from C6 glioma cells which was inhibited in the presence o f IL -lra. Serotonin and
melatonin do not directly stimulate IL-6 release alone or in the presence o f IL -ip.
Therefore, I accept the null hypotheses that serotonin and melatonin do not have an effect
on the release o f lL-6 by themselves or in the presence o f EL-ip. Currently under
investigation are the potential inhibitory effects serotonin may have on EPT and IL -ip
synergistic release o f IL-6 from C6 glioma cells.
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Table 1. Mammalian 5-HT Receptor Subtypes and Their Signal Transduction Pathway
(adapted from Cooper et al., 1996).
Receptor
Subtype

G-Protein

5-HTi Family

5-HT lA, IB. ID. IE

Gi

Inhibition o f Adenylyl Cyclase

5 -HT 2

5 -H T 2A.2B.2C

Gq

Phosphoinositide Hydrolysis

5-HT 4

Gs

Activation o f Adenylyl Cyclase

5-HT 5A.5B

?

Unknown coupling mechanism

5-HT 6

Gs

Activation o f Adenylyl Cyclase

5-HT 7

Gs

Activation o f Adenylyl Cyclase

5-HT 3

None

G-Protein Coupled
Receptors

Family

Others

Ligand-Gated Ion
Channel
G,
Gs
Gq

Signal Transduction Pathway

Ligand-Gated Ion Channel
(mostly on neurons)

Inhibitory G-Protein Associated Receptor
Stimulatory G-Protein Associated Receptor
Phosphoinositide G-Protein Associated Receptor
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Table 2. Comparison o f IL-6 ELISA and 7TDI Standard Curves.
IL-6 ELISA
Line-of-Best Fit
Equation o f the Line

Detection Limit

7TDI Bioassay

4-Parameter Curve

Linear Regression

Logarithmic

y = (a-d)/(l+(x/c)''b)+d

y = mx + b

y = mLn(x) + b

0.25 ng/mL

5 pg/mL

2 pg/mL

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPENDIX n

LIST OF FIGURES

45

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

46
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Hypophysial Arteries
(Prim ary Plexus)

Anterior
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Hypophysial Portal Vessels
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Figure I. Vascularization o f the pituitary gland bv hvpophvsial arteries and portal
vessels in relation to the hypothalamus.
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Figure 2. Biosynthesis of Catecholamines.
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idenytyl

Plasma Membrane

cAMP

Figure 3. G-protein Signal Transduction. A neurotransminer (A or B) binds to the select
receptor (Rs or Ri) resulting in an appropriate cellular response. When A binds to a
receptor with stimulatory efifects (Rs), the Rs associates with a Gs subtype protein. The
resulting cellular response is activation o f adenylyl cyclase leading to the production o f
cAMP. When B binds to a receptor with inhibitory effects (Ri). the Ri associates with the
Gi subtype protein thereby inhibiting adenylyl cyclase and the production o f cAMP.
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Figure 4. Synthesis and Metabolism o f Serotonin.
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Day 1:
Coat wells with DL-6
( 100 fjL/well)

Incubate IL-6 or Sample with
Rabbit anti-rat IL-6 Antibody

Rinse Plate
3 X with PBST

Bound and Free Antibody

Day 2:
Add incubated samples (150 ^iL/well) to the rinsed plate and incubate
3 h at ambient temperature
(Free Antibody Binds IL-6 Coated to Plate)
Rinse Plate 3 x with PBST

Add HRP Labeled Goat anti-rabbit Antibody (150 ^L/well)
and incubate 2 h at ambient temperature
(Secondary Antibody binds Primary Antibody)
Rinse Plate 3 x with PBST

Add TMB substrate solution ( 100 pL/well)
Color Develops within 10-20 min
Blue Color Deyelops

Add 0.25 M HCl Stopping Solution (100 pL/well)
Read Plate within 5 min at 450 nm on plate reader
(Blue Color Turns Yellow)

Figure 5. General Schematic for the IL-6 ELISA.
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C

D..
Log Concentration

Figure 6. Four Parameter Logistic Curve Model. The equation o f the line consists o f the
following four parameters: A equals the upper asymptote, B equals the slope o f the linear
portion o f the curve and C is the IC50 and D is the lower asymptote. The curve is
sigmoidal in shape and graphed on a logarithmic x-axis scale.
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Figure 7. Checkerboard titration of IL-6 antigen plotted against the absnrhanrt»
for each anti-rat IL-6 antibody dilution. Varying amounts of IL-6 (0 to 6
ng/well) were incubated with diluted antibody (1:500 to 1:64,000) for 2 h
(following the ELISA optimization procedure). Each data point represents one
observation.
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Figure 8. Checkerboard Titration o f IL-6 antigen plotted against the absorbance
for each anti-rat IL-6 antibody dilution. Varying amounts o f IL-6 (0 to 6 ng/well)
were incubated with diluted antibody (1:1000 to 1:2000) for 2 h (following the
ELISA optimization procedure). Data are presented as the mean ± SEM of each
antigen concentration consisting of triplicate observations per concentration.
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Figure 9. Checkerboard titration o f anti-rat IL-6 antibody duiutions against
absorbance for each IL-6 coating antigen concentration. Varying amounts o f
IL-6 (0 to 6 ng/well) were incubated with dulted antibody (1:500 to 1:64,000)
for 2 h (following the ELISA optimization procedure). Each data point
represents one observation.
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Figure 10. Checkerboard titration o f anti-rat IL-6 antibody dilutions against
absorbance for each IL-6 coating antigen concentration. Varying amounts of IL-6
(0 to 6 ng/well) were incubated with diluted antibody (1:1000 to 1:2000) for 2 h
(following the ELISA optimization procedure). Data are presented as the mean ±
SEM of each antibody dilution consisting o f triplicate observations per dilution.
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Figure 11. IL-6 ELISA Standard Curve. Four-parameter logistic calibration curve with a
R." value o f 0.99 and an
value o f 3 1 ng/mL. Equation parameters for the upper and
lower asymptopes are 0.77 and 0.05 respectively, and 1.09 for the slope o f the linear
portion o f the curve. The data are expressed as the mean ^ SEM for points consisting
o f three observations.
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Figure 12. Matrix Effects. Standard curves were generated using PBST, sfRPMI, and
1.0% serum containing RPMI as the matrix. IL-6 (0.5 to 100 ng/mL) standard dilutions
were made into each matrix and incubated with anti-rat IL-6 antibody (following IL-6
ELISA protocol). Four-parameter curve fitting resulted in IC50 values o f 5.54, 5.41,4.89
respectiv ely. The data are presented as the mean ± SEM for each group consisting o f
three observations per group.
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Figure 13. 7T D 1 cell hinassay standard curve with a linear regression line
of-best fit equation. Cells were cultured for 72 h in the absence or
presence o f increasing amounts o f rmIL-6. Optical density values were
obtained with M TT, as described in text. The data presented are a mean
± SEM for points consisting o f four observations.
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Figure 14. 7TD1 cell bioassav standard curve with a loparithmic Ihie-ogbest fit equation. Cells were cultured for 72 h in the absence or presence
o f increasing amounts o f imIL-6. Optical density values were obtained
with MTT, as described in text. The data presented the mean ± SEM for
each point consisting o f four observations.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

60

200
180 50
160 -

20
140 -

120

-

100

-

0.2

80 -

60 -

40 -

20

-

8

12

24

36

48

Time (h)

Figure 15. Interleukin 1p srimulates IL-6 release from C6 glinma cells Cultured C6
cells ( 100 X 10^ cellsAveU) were exposed to either vehicle (sfRPMI) or different
concentrations o f IL -ip from 8 • 48 h. IL^ip stimulated IL-6 release at 24 h, 36 h,
and 48 h. The standard error bars are not shown,but for the 8 and 12 h time groiqis
the %SEM was less than 20% and for the 24, 36, and 48 time groups the %SEM
was less than 10%.
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Figure 16. Interleukin-IB stimulates IL-6 release from C6 glioma cells.
Cultured C6 cells (100 x 10^ cells/well) were exposed to either vehicle
(sfRPMI) or difiFerent concentrations o f IL-ip for 24 h. The data are
presented as the mean ± SEM for concentration groups consisting o f
four observations per group.
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Figure 17. Effects o f IL-lra and IL-lB on IL-6 release from C6 glioma cells.
C6 cells (100 X 10^ cells/well) were exposed to either vehicle (sfRPMI), IL-lra
(100 ng/mL), IL -ip (10 or 50 ng/mL), and IL-lra + IL-I(3 for 24 h. The data
are expressed as the mean ± SEM o f each treatment group consisting o f four
observations per group.
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Figure 18. Effects o f Serotonin and IL-lB on the Release of IL-6 from C6 glioma
cells. C6 cells (100 x 10^ cells/well) were incubated with vehicle (sfRPMI), IL -l3
(50 ng/mL), serotonin (0.5 to 100 jiM), or IL-l 3 + serotonin for 24 b. The data are
expressed as the mean ± SEM of each treatment group consisting o f four
observations per group.
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Figure 19. Effects o f Serotonin and IL-1B on IL-6 Release from C6 glioma cells.
C6 cells (100 X 10^ cells/well) were incubated in the presence o f vehicle (sfRPMI),
isoproterenol (IPT) (10 jaM), IL-ip (10 and 50 ng/mL), IPT 4- IL -l3, serotonin (I to
100 nM), or serotonin 4- IL -l3 for 24 h. The data are presented as the mean ± SEM
o f each treament group consisting of 4 observations per group.

Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout

permission.

65
400
■ Vehicle
00 Isoproterenol (10 uM)
350 0 IL-lB (10 ng/mL)
S IL-16 (10 ng/mL) + Isoproterenol
300 -

S IL-16 (50 ng/mL)
S IL-16 (50 ng/mL)

250 -

■ Melatonin
S Melatonin + IL -16 (10 ng/mL)

<ü
'£û
CL

Isoproterenol

□ Melatonin -r EL-16 (50 ng/mL)

200

o

I

150 i

100

-

1
Controls

I

10

100

Concentration o f Melatonin (nM)
Figure 20. Effects o f Melatonin and IL-IB on IL-6 Release from C6 glioma cells.
C6 cells (100 X 10^ cells/well) were incubated in the presence o f vehicle (sfRPMI),
isoproterenol (IPT) (10 uM), IL-ip (10 and 50 ng/mL), IPT + IL-ip, melatonin
(1 to 100 nM), or melatonin -r- IL-ip for 24 h. The data are presented as the mean
= SEM o f each treament group consisting o f four observations per group.
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Figure 21. Eflfects o f serum cnntaininp RPMI and H ^ ip on IL-6 release. C6 cells
( 100 X 10^ cells/well) were exposed to differenct concentrations o f IL -ip (0.2 to
100 ng/mL) in serum-free RPMI (sfRPMI), 0.1%, 1%, or conçlete RPMI. The
data are presented as the mean ± SEM o f groups consisting o f four observations
per group.
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R elease. C6 cells (100 x 10^ cells/well) were incubated in the presence o f vehicle
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serotonin for 24 h. The data are presented as the mean ± SEM o f each group
consisting o f four observations per group.
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